Skip Navigation



JAC Advance Access published online on December 2, 2005
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dki437
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
57/2/279    most recent
dki437v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Jones, R. N.
Right arrow Articles by Sader, H. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jones, R. N.
Right arrow Articles by Sader, H. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Received September 8, 2005
Revised November 3, 2005
Accepted November 6, 2005

Original article

Oxazolidinone susceptibility patterns in 2004: report from the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations

Ronald N. Jones 1 *, James E. Ross 2, Thomas R. Fritsche 2, and Helio S. Sader 2

1 JMI Laboratories, Inc., 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA; Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA
2 JMI Laboratories, Inc., 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA

* To whom correspondence should be addressed.
Ronald N. Jones, E-mail: ronald-jones{at}jmilabs.com


  Abstract

Objectives: To investigate the activity of linezolid (an oxazolidinone), a potent choice for community- and hospital-acquired infections, via a worldwide surveillance network called the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program.

Methods: A total of 4098 Gram-positive strains were collected from 42 laboratories located in North America (five sites in Canada), South America (10 sites), Europe (16 sites) and the Far East (11 sites). Each country or site submitted 200 isolates (Canada submitted 200 isolates for each of five sites; total 1000) for confirmation of organism identification and reference MIC processing. Nearly 25 comparator agents were tested along with quality control strains, and interpretative criteria from the CLSI, formerly the NCCLS, M100-S15 were applied. No linezolid resistance was detected in strains from 16 monitored countries in 2004.

Results: Linezolid remained highly active against Streptococcus pneumoniae, viridans group and {beta}-haemolytic streptococci (MIC90, 1 mg/L). Against Staphylococcus aureus, linezolid showed 99.5% of results at 0.5-2 mg/L with only one isolate at 4 mg/L. Oxacillin-resistant S. aureus rates varied between nations and ranged from 1.4% in Sweden to 29.5% in the UK to 65.2% in Mexico. Linezolid MIC values were generally one log2 dilution step lower for coagulase-negative staphylococci (CoNS) when compared with S. aureus. No CoNS strains produced a linezolid result at 4 mg/L. Compared with ZAAPS 2002 and 2003 results for enterococci where seven resistant strains were identified, the 2004 data revealed no resistance and 98.1% of linezolid MIC results were at 1 or 2 mg/L. Vancomycin-resistant enterococci (5.3% overall) varied markedly by country including a high of 47.2% in Korea.

Conclusions: Linezolid continues to be effective in vitro against Gram-positive pathogens from five continents and no oxazolidinone-resistant strains were identified among the 4098 systemically collected strains (2004) or among 20 158 non-United States isolates for the entire ZAAPS Program (2002-04).

Keywords: linezolid; MRSA; VRE; surveillance.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
H. S. Sader, R. N. Jones, K. L. Rossi, and M. J. Rybak
Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals
J. Antimicrob. Chemother., November 1, 2009; 64(5): 1024 - 1028.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
E. Skripkin, T. S. McConnell, J. DeVito, L. Lawrence, J. A. Ippolito, E. M. Duffy, J. Sutcliffe, and F. Franceschi
R{chi}-01, a New Family of Oxazolidinones That Overcome Ribosome-Based Linezolid Resistance
Antimicrob. Agents Chemother., October 1, 2008; 52(10): 3550 - 3557.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
L. Lawrence, P. Danese, J. DeVito, F. Franceschi, and J. Sutcliffe
In Vitro Activities of the Rx-01 Oxazolidinones against Hospital and Community Pathogens
Antimicrob. Agents Chemother., May 1, 2008; 52(5): 1653 - 1662.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
S. Kelly, J. Collins, M. Maguire, C. Gowing, M. Flanagan, M. Donnelly, and P. G. Murphy
An outbreak of colonization with linezolid-resistant Staphylococcus epidermidis in an intensive therapy unit
J. Antimicrob. Chemother., April 1, 2008; 61(4): 901 - 907.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. Tsakris, S. K. Pillai, H. S. Gold, C. Thauvin-Eliopoulos, L. Venkataraman, C. Wennersten, R. C. Moellering Jr, and G. M. Eliopoulos
Persistence of rRNA operon mutated copies and rapid re-emergence of linezolid resistance in Staphylococcus aureus
J. Antimicrob. Chemother., September 1, 2007; 60(3): 649 - 651.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
A. Soriano, M. Ortega, S. Garcia, G. Penarroja, A. Bove, M. Marcos, J. C. Martinez, J. A. Martinez, and J. Mensa
Comparative Study of the Effects of Pyridoxine, Rifampin, and Renal Function on Hematological Adverse Events Induced by Linezolid
Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2559 - 2563.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
R. N. Jones, M. G. Stilwell, P. A. Hogan, and D. J. Sheehan
Activity of Linezolid against 3,251 Strains of Uncommonly Isolated Gram-Positive Organisms: Report from the SENTRY Antimicrobial Surveillance Program
Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1491 - 1493.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
S. Kelly, J. Collins, M. Davin, C. Gowing, and P. G. Murphy
Linezolid resistance in coagulase-negative staphylococci1
J. Antimicrob. Chemother., October 1, 2006; 58(4): 898 - 899.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
R. N. Jones, J. E. Ross, T. R. Fritsche, and H. S. Sader
Comment on: Linezolid resistance in coagulase-negative staphylococci2
J. Antimicrob. Chemother., October 1, 2006; 58(4): 899 - 900.
[Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
L. Vera-Cabrera, E. Gonzalez, A. Rendon, J. Ocampo-Candiani, O. Welsh, V. M. Velazquez-Moreno, S. Hak Choi, and C. Molina-Torres
In Vitro Activities of DA-7157 and DA-7218 against Mycobacterium tuberculosis and Nocardia brasiliensis.
Antimicrob. Agents Chemother., September 1, 2006; 50(9): 3170 - 3172.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.